The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

On June 12, SpaceX (NASDAQ: SPCX) had the biggest IPO on record, making $75 billion (1) — but shares are already dropping (2). Entrepreneur and NYU professor Scott Galloway isn’t impressed.

“Getting the Nasdaq to waive requirements applied to every company until now, so he can force index funds to purchase shares, aims a demand cannon of $75B at a business with a small float. The result is a price that in no way reflects the underlying value,” wrote Galloway in a June 17 Medium post (3). “But I digress. This isn’t an investment, but a trade. So … where to ‘invest’?”

Robert Kiyosaki says this 1 asset will surge 400% in a year and begs investors not to miss this ‘explosion’

Millionaires under 43 hold only 25% of their wealth in stocks. Surprised? Here’s where their money is actually going

Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — here are 5 ways to build wealth like a landlord without actually being one

Galloway says you should forget SpaceX stock and invest in GLP-1s instead.

“Five years ago, when Ozempic and Wegovy were first approved for weight loss, GLP-1s looked like a silver bullet for obesity,” Galloway wrote. “Today, they’re a fully loaded magazine of silver bullets aimed at obesity, addiction, cancer, sleep apnea, and a growing list of other diseases and chronic conditions.”

Here’s what Galloway had to say about which GLP-1 producers make for a good investment — and what needs to change for GLP-1s to be even more successful.

Galloway says that the pharmaceutical company Eli Lilly is doing especially well thanks to the weight loss drug.

He says that Eli Lilly’s shares have seen a 418% price increase since 2021, when GLP-1s were approved for weight loss. According to Eli Lilly’s historic price lookup page, its stock price was $276.22 at the end of 2021. By the end of 2025, its stock was worth $1,074.68 (4).

The company is currently working on a new GLP-1 drug, a combination drug with promising phase 3 results (5). If successful, this medication could help Eli Lilly’s stock climb even higher.

In comparison, fellow GLP-1 creator Novo Nordisk hasn’t seen the same level of success. Galloway says that might be because Eli Lilly has had a better time marketing directly to consumers.

“In the GLP-1 category, we observe prices are elastic. The more we lower the price, the more users we get,” says Eli Lilly Chair and CEO David Ricks. “That’s the path we’re on.”

Galloway also says that GLP-1s almost work like a subscription, because people who get on them tend to stay on them.

Read More: Robert Kiyosaki has a grim warning for baby boomers. This is what he recommends to protect your wealth

The main reason people stop taking GLP-1s is the price, according to the Cleveland Clinic (6).

GLP-1s are expensive, costing hundreds of dollars per month (7) or more. And increasingly, insurance isn’t agreeing to pay for it (8). Lowering drug prices provides real support for people who were previously accessing the drug through their insurance before losing coverage.

Eli Lilly has partnered with the U.S. government to allow seniors on Medicaid D to pay only $50 per month for the drug (9). It’s also offered self-pay options for patients who are uninsured, or whose insurance won’t cover it — but its prices are still expensive, requiring people to pay up to $449 per multi-dose pen.

“The GLP-1 story offers something Silicon Valley used to produce in abundance: a hopeful vision of the future,” says Galloway. “The question isn’t whether GLP-1s will change the U.S. They already have. The question is whether we’ll be stupid enough to ration the change.”

Dave Ramsey warns this is America's most common retirement mistake — here's what it is and how to fix it ASAP

Insurance companies profit most from drivers who auto-renew without shopping around. Comparing 100+ quotes takes 2 minutes and costs nothing

The new tax breaks in Trump's 'big beautiful bill' expire after 2028 — and financial experts say most people won't act in time. Here's what to do before the window closes

The average American overpays for at least one of these 5 monthly bills they never think to question. Which of these are draining your budget?

Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.

We rely only on vetted sources and credible third-party reporting. For details, see our ethics and guidelines.

NPR (1), (8); Reuters (2); Medium (3); Eli Lilly and Company (4), (5), (9); Cleveland Clinic (6); Maven Clinic (7)

This article originally appeared on Moneywise.com under the title: Scott Galloway says GLP-1 drugs are a 'silver bullet' for America's woes, if we're not 'stupid enough' to get in the way

This article provides information only and should not be construed as advice. It is provided without warranty of any kind.